N/A N=11 Treatment

Blue Light Phototherapy

Grover's Disease · Psoriasis Vulgaris

Bottom Line

View on ClinicalTrials.gov: NCT04343586 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2023

Primary outcome: Primary: Efficacy of Blue Light Therapy for Patients With Grover's Disease — 27; 6 lesion count

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Blue light phototherapy (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Northwestern University
Primary completion: Dec 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Efficacy of Blue Light Therapy for Patients With Grover's Disease	27; 6	—
PRIMARY Assess User Experience With the Dermatology Life Quality Index (DLQI) Pre and Post-treatment.	4.3; 2.3	—

Summary

This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.

Eligibility Criteria

Inclusion Criteria

Patient's aged 18-89 at time of enrollment
Previous diagnosis of psoriasis vulgaris or Grover's disease

Exclusion Criteria

All Groups: Subjects who are younger than 18 years of age or older than 90 years of age
Patients who have received topical or systemic treatment within the prior 2 weeks of planned phototherapy
Patients prescribed any of the following drugs for issues not related to their psoriasis or Grover's disease
topical steroids
calcineurin inhibitors
methotrexate
retinoids
biologic agents
Unable to schedule phototherapy sessions
We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04343586). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.